toripalimab subcutaneous (JS001sc) / Shanghai Junshi Biosci 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
toripalimab subcutaneous (JS001sc) / Shanghai Junshi Biosci
NCT06505837: JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）

Recruiting
3
356
RoW
Arm1: JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy, Arm 2: JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy
Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
06/25
12/26
First-line treatment for recurrent or metastatic non-squamous non-small cell lung cancer, ChiCTR2400084442: A multicenter, open, randomized controlled, Phase III study comparing the pharmacokinetic profile, efficacy, and safety of Toripalimab injection (subcutaneous injection) (JS001sc) and Toripalimab injection (JS001) in combination with standard chemotherapy as first-line treatment for relapsed or metastatic non-squamous non-small cell lung cancer

Not yet recruiting
3
356
 
JS001sc; JS001
hunan cancer hospital; hunan cancer hospital, Shanghai Junshi Biosciences Co., Ltd.
Recurrent or metastatic non-squamous NSCLC
 
 
9MW2821-2023-CP104, CTR20232677: An open-label, single-arm, multicenter Phase Ib/II clinical study evaluating the safety and efficacy of 9MW2821 in combination with toripalimab injection in patients with locally advanced or metastatic urothelial carcinoma

Ongoing
1b/2
100
China
9MW2821 - Mabwell (Shanghai) Biosci, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci
Jiangsu Maweikang New Drug R&D Co., Ltd
Urothelial carcinoma
 
 
NCT05751486: A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

Recruiting
1
24
RoW
Toripalimab injection(subcutaneous)/JS001sc, Toripalimab /JS001
Shanghai Junshi Bioscience Co., Ltd.
Advanced Nasopharyngeal Carcinoma
12/23
12/25

Download Options